当前位置: X-MOL 学术Int. J. Endocrinol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Effects of Liraglutide on Left Ventricular Function: A Meta-Analysis of Randomized, Placebo-Controlled Trials
International Journal of Endocrinology ( IF 2.3 ) Pub Date : 2021-06-15 , DOI: 10.1155/2021/9993229
Zhaoshuang Zhong 1 , Kaiming Chen 2 , Yan Zhao 1 , Shuyue Xia 1
Affiliation  

Background. The effects of liraglutide treatment on the left ventricular systolic and diastolic function remain unclear. Methods. This meta-analysis was conducted according to the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement. All relevant randomized, placebo-controlled trials (RCTs) were identified by searching PubMed, EMBASE, Cochrane Library, and ISI Web of Science from the establishment to January 2021 without language limitations. The weighted mean difference (WMD) with 95% confidence intervals (CIs) was calculated. Results. Ten placebo-controlled RCTs involving a total of 732 cases were included in the meta-analysis. Compared with the placebo group, liraglutide therapy showed no beneficial effect on the left ventricular ejection fraction (LVEF) at the end of the study (WMD: 2.120, 95% CI: −0.688 to 4.929, ) and ΔLVEF during the trial period (WMD: −0.651, 95% CI: −1.649 to 0.348, ). Similarly, no statistical differences were noted in diastolic function parameters between the two groups, including the value early diastolic filling velocity (E)/the mitral annular early diastolic velocity () (WMD: −0.763, 95% CI: −2.157 to 0.630, ), (WMD: −0.069, 95% CI: −0.481 to 0.343, ), and (WMD: −0.683, 95% CI: −1.663 to 0.298, ). Conclusions. Liraglutide treatment did not improve the left ventricular systolic and diastolic function. Given the study’s limitations, further investigation may be warranted.

中文翻译:

利拉鲁肽对左心室功能的影响:随机、安慰剂对照试验的荟萃分析

背景。利拉鲁肽治疗对左心室收缩和舒张功能的影响尚不清楚。方法。该荟萃分析是根据系统评价和荟萃分析 (PRISMA) 声明的首选报告项目进行的。通过在 PubMed、EMBASE、Cochrane 图书馆和 ISI Web of Science 中搜索从成立到 2021 年 1 月的所有相关随机、安慰剂对照试验 (RCT),没有语言限制。计算了具有 95% 置信区间 (CI) 的加权平均差 (WMD)。结果. 荟萃分析中纳入了 10 项安慰剂对照 RCT,共涉及 732 例病例。与安慰剂组相比,利拉鲁肽治疗在研究结束时对左心室射血分数 (LVEF) 没有显示出有益影响(WMD:2.120,95% CI:-0.688 至 4.929,)和 ΔLVEF (WMD: -0.651, 95% CI: -1.649 to 0.348,)。同样,两组之间的舒张功能参数也没有统计学差异,包括舒张早期充盈速度( E)/二尖瓣环早期舒张速度((WMD:-0.763,95% CI:-2.157至0.630,), (WMD: -0.069, 95% CI: -0.481 to 0.343,), (WMD:-0.683,95% CI:-1.663 到 0.298, )。 结论。利拉鲁肽治疗未改善左心室收缩和舒张功能。鉴于该研究的局限性,可能需要进一步调查。
更新日期:2021-06-15
down
wechat
bug